256 related articles for article (PubMed ID: 11929146)
1. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.
Dittrich E; Schillinger M; Sunder-Plassmann G; Hörl WH; Vychytil A
Perit Dial Int; 2002; 22(1):60-6. PubMed ID: 11929146
[TBL] [Abstract][Full Text] [Related]
2. Iron supplementation in haemodialysis--practical clinical guidelines.
Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
[TBL] [Abstract][Full Text] [Related]
3. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
4. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia.
Li H; Wang SX
Perit Dial Int; 2008; 28(2):149-54. PubMed ID: 18332450
[TBL] [Abstract][Full Text] [Related]
5. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
6. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
Li H; Wang SX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
[TBL] [Abstract][Full Text] [Related]
7. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
[TBL] [Abstract][Full Text] [Related]
8. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients.
Chuang CL; Liu RS; Wei YH; Huang TP; Tarng DC
Nephrol Dial Transplant; 2003 Feb; 18(2):370-7. PubMed ID: 12543894
[TBL] [Abstract][Full Text] [Related]
9. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
10. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
Ogi M; Horiuchi T; Abe R; Wakabayashi M; Wakabayashi T
Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737
[TBL] [Abstract][Full Text] [Related]
12. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
13. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin.
Stoves J; Inglis H; Newstead CG
Nephrol Dial Transplant; 2001 May; 16(5):967-74. PubMed ID: 11328902
[TBL] [Abstract][Full Text] [Related]
14. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment.
Kulnigg S; Teischinger L; Dejaco C; Waldhör T; Gasche C
Am J Gastroenterol; 2009 Jun; 104(6):1460-7. PubMed ID: 19491860
[TBL] [Abstract][Full Text] [Related]
15. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.
Kosch M; Bahner U; Bettger H; Matzkies F; Teschner M; Schaefer RM
Nephrol Dial Transplant; 2001 Jun; 16(6):1239-44. PubMed ID: 11390726
[TBL] [Abstract][Full Text] [Related]
17. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
Ahluwalia N; Skikne BS; Savin V; Chonko A
Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
[TBL] [Abstract][Full Text] [Related]
18. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
[TBL] [Abstract][Full Text] [Related]
19. [Anemia in peritoneal dialysis patients].
Lausević M; Nesić V; Jovanović N; Stojimirović B
Srp Arh Celok Lek; 2006; 134(3-4):133-7. PubMed ID: 16915754
[TBL] [Abstract][Full Text] [Related]
20. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
Silverberg DS; Iaina A; Peer G; Kaplan E; Levi BA; Frank N; Steinbruch S; Blum M
Am J Kidney Dis; 1996 Feb; 27(2):234-8. PubMed ID: 8659499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
